VSTM - ベラステム (Verastem Inc.)

VSTMのニュース

   Verastem, Inc. (NASDAQ:VSTM) Short Interest Down 13.5% in September  2020/10/22 06:45:00 Stock Observer
Verastem, Inc. (NASDAQ:VSTM) was the target of a large decline in short interest in September. As of September 30th, there was short interest totalling 10,070,000 shares, a decline of 13.5% from the September 15th total of 11,640,000 shares. Based on an average daily volume of 4,060,000 shares, the short-interest ratio is currently 2.5 days. Several […]
   Verastem, Inc. (NASDAQ:VSTM) Sees Large Drop in Short Interest  2020/10/21 06:44:46 Zolmax News
Verastem, Inc. (NASDAQ:VSTM) was the recipient of a large decline in short interest in September. As of September 30th, there was short interest totalling 10,070,000 shares, a decline of 13.5% from the September 15th total of 11,640,000 shares. Based on an average daily volume of 4,060,000 shares, the days-to-cover ratio is currently 2.5 days. Large […]
   The Play On Verastem (NASDAQ:VSTM)  2020/09/13 13:55:25 Seeking Alpha
Today, we revisit Verastem. The company recently out-licensed its primary compound to focus on developing earlier stage compounds in its pipeline.
   The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference  2020/09/13 13:49:45 Benzinga
Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market. The week also witnessed a flurry of news flow on the coronavirus vaccine front. Even as nine vaccine makers released a pledge to put safety first, AstraZeneca plc (NYSE: AZN ) was forced to voluntarily stall the late-stage study of its coronavirus vaccine, citing an unidentified illness in one of the trial participants. Clinical trials were allowed to resume on Sept. 12. Still, clinical trial readouts led to wild swings in some stocks. Here are the key catalysts for the unfolding week: Conferences: The International Parkinson and Movement Disorder Society, or MDS, Virtual Congress 2020: Sept. 12–16. H.C. Wainwright Virtual Healthcare Conference: Sept. 14-16 2nd RAS- Targeted Drug Development Summit 2020: Sept. 14-16 18th Annual Morgan Stanley Healthcare Conference: Sept. 14-18 2020 Cantor Global Virtual Healthcare Conference: Sept. 15-17 European Society for Medical Oncology, or ESMO, Virtual Congress 2020: Sept. 14-21 PDUFA Dates The FDA is set to rule on Bausch Health Companies Inc.'s (NYSE: BHC ) NDA for EM-100, a ketotifen preservative-free ophthalmic solution that is being evaluated for allergic conjunctivitis.
   Did Hedge Funds Make The Right Call On Verastem Inc (VSTM) ?  2020/08/12 13:43:18 Yahoo Finance
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend
   Did Hedge Funds Make The Right Call On Verastem Inc (VSTM) ?  2020/08/12 13:43:18 Yahoo Finance
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend
   Are Options Traders Betting on a Big Move in Verastem (VSTM) Stock?  2020/05/18 15:20:00 Zacks Investment Research
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   Is Verastem (VSTM) Stock Outpacing Its Medical Peers This Year?  2020/05/01 15:30:17 Zacks Investment Research
Is (VSTM) Outperforming Other Medical Stocks This Year?
   Is the Options Market Predicting a Spike in Verastem (VSTM) Stock?  2020/04/15 13:30:00 Zacks Investment Research
Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.
   Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up  2020/01/09 08:00:00 Zacks Investment Research
Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.
   Verastem Oncology Announces Submission of a Marketing Authorization Application to the European Medicines Agency for COPIKTRA® (duvelisib)  2019/11/25 12:00:00 Business Wire
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeki
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
   The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing  2019/11/14 13:07:04 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 13.) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bausch Health Companies Inc (NYSE: BHC ) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) (reacted to its third-quarter results) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (reacted to its third-quarter results) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Opiant Pharmaceuticals Inc (NASDAQ: OPNT ) ( reported an unexpected profit for its third quarter) Recro Pharma Inc (NASDAQ: REPH ) Seattle Genetics, Inc. (NASDAQ: SGEN ): filed an arbitration demand to settle dispute with DAIICHI SANKYO/S ADR (OTC: DSNKY ).
   The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher  2019/11/13 12:10:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) Crispr Therapeutics AG (NASDAQ: CRSP ) Diplomat Pharmacy Inc (NYSE: DPLO )( warned of going concern risk) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) XOMA Corp (NASDAQ: XOMA ) Zai Lab Ltd (NASDAQ: ZLAB ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov.

calendar